Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sequence matters: Total body irradiation (TBI)-based myeloablative conditioning with post-transplant cyclophosphamide may reduce the early nonrelapse mortality compared with pretransplant cyclophosphamide plus TBI.
Redondo S, García-Cadenas I, Vila A, Esquirol A, Portos JM, Novelli S, Saavedra S, Moreno C, Garrido A, Arguello-Tomas M, Oñate G, López-Pardo J, Caballero AC, Miqueleiz S, Briones J, Sierra J, Sancho G, Martino R. Redondo S, et al. Eur J Haematol. 2023 Jul;111(1):146-153. doi: 10.1111/ejh.13978. Epub 2023 Apr 14. Eur J Haematol. 2023. PMID: 37058419
Feasibility of a New Model of Care for Allogeneic Stem Cell Transplantation Recipients Facilitated by eHealth: The MY-Medula Pilot Study.
Redondo S, De Dios A, Gomis-Pastor M, Esquirol A, Aso O, Triquell M, Moreno ME, Riba M, Ruiz J, Blasco A, Tobajas E, González I, Sierra J, Martino R, García-Cadenas I. Redondo S, et al. Transplant Cell Ther. 2023 Jun;29(6):385.e1-385.e8. doi: 10.1016/j.jtct.2023.03.016. Epub 2023 Mar 21. Transplant Cell Ther. 2023. PMID: 36948273 Free article.
Successful Outcome in Patients with Myelofibrosis Undergoing Allogeneic Donor Hematopoietic Cell Transplantation Using Reduced Doses of Post-Transplantation Cyclophosphamide: Challenges and Review of the Literature.
García-Cadenas I, Redondo S, Esquirol A, Portos JM, Novelli S, Saavedra S, Moreno C, Garrido A, Oñate G, López J, Caballero AC, Miqueleiz S, Arguello-Tomas M, Briones J, Sierra J, Martino R. García-Cadenas I, et al. Among authors: redondo s. Transplant Cell Ther. 2023 Jul;29(7):473.e1-473.e6. doi: 10.1016/j.jtct.2023.04.008. Epub 2023 Apr 20. Transplant Cell Ther. 2023. PMID: 37086849 Free article. Review.
Optimization of a home hospitalization program for hematopoietic stem cell transplantation with ehealth integration and clinical pharmacist involvement.
Moreno-Martinez ME, Riba M, García-Cadenas I, Esquirol A, Yusta M, Redondo S, De Dios A, Portos JM, Aso O, Marcos-Fendian A, Font N, Briones J, Martino R, Feliu A. Moreno-Martinez ME, et al. Among authors: redondo s. Front Immunol. 2024 Jun 11;15:1397115. doi: 10.3389/fimmu.2024.1397115. eCollection 2024. Front Immunol. 2024. PMID: 38919607 Free PMC article.
Comparison of Three Graft-versus-Host Disease Prophylaxis Strategies after T Cell-Replete Haploidentical Hematopoietic Transplantation: Tacrolimus versus Calcineurin Inhibitors + Mycophenolate Mofetil versus Sirolimus + Mycophenolate Mofetil.
Esquirol A, Pascual MJ, Montoro J, Piñana JL, Ferrà C, Herruzo B, Garcia-Cadenas I, Balaguer A, Perez A, Huguet M, Redondo S, Villalba M, Hernandez-Boluda JC, Chorao P, Hernani R, Sanz J, Solano C, Sierra J, Martino R. Esquirol A, et al. Among authors: redondo s. Transplant Cell Ther. 2024 Oct;30(10):1025.e1-1025.e14. doi: 10.1016/j.jtct.2024.07.027. Epub 2024 Aug 6. Transplant Cell Ther. 2024. PMID: 39116938
Severity and organ distribution of graft-versus-host disease with post-transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA-matched or single-allele mismatched stem cell transplantation.
Redondo S, García-Cadenas I, Esquirol A, Portos JM, Iranzo E, Arguello-Tomas M, Saavedra S, Oñate G, Caballero AC, Garrido A, López J, Muntañola A, Paviglianiti A, Miqueleiz S, Sierra J, Briones J, Martino R. Redondo S, et al. Eur J Haematol. 2024 Dec;113(6):776-787. doi: 10.1111/ejh.14294. Epub 2024 Aug 18. Eur J Haematol. 2024. PMID: 39155459
Development and Clinical Validation of Liquid Chromatography-Tandem Mass Spectrometry for Measuring Ruxolitinib in Steroid-Refractory Graft-Versus-Host Disease: A First Step Towards Optimized Treatment.
Redondo S, Costa M, Moreno-Martinez ME, Arguello-Tomas M, Riba M, Aso O, Iranzo E, Esquirol A, Sierra J, Briones J, Martino R, Zapico E, García-Cadenas I. Redondo S, et al. Eur J Haematol. 2024 Nov 15. doi: 10.1111/ejh.14349. Online ahead of print. Eur J Haematol. 2024. PMID: 39545520
Ruxolitinib in acute and chronic graft-versus-host disease: real life long-term experience in a multi-center study for adult and pediatric patients, on behalf of the GETH-TC.
Escamilla-Gómez V, García Gutiérrez V, Alcalde-Mellado P, Astibia-Mahillo B, Chinea-Rodriguez A, López-Corral L, Acera-Gómez M, Torres Ochando MK, Borrero Borrego A, González Pinedo L, Zudaire Ripa T, González Vicent M, Benzaquén A, Izquierdo Garcia I, Asensi Cantó P, Montoro J, Martín-Domínguez FM, Orti G, Valcárcel D, Benitez-Carabante MI, Diaz-de-Heredia C, Cañamero E, Ferrá C, García-Cadenas I, Redondo S, Sisinni L, Perez-Martínez A, Mussetti A, Garcia-Mañó L, Palomo-Moraleda MDP, González-Sierra PA, Jurado M, Perez-Simon JA; GETH-TC. Escamilla-Gómez V, et al. Among authors: redondo s. Bone Marrow Transplant. 2024 Dec 11. doi: 10.1038/s41409-024-02483-0. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 39663471
82 results